source
- Swiss biotech Windward Bio raises $175 million in IPO to fund lung-drug development and test Tezspire competitorWindward Bio, a Swiss immune‑drug developer, completed a $175 million initial public offering, selling about 10.3 million shares at $17 each. The company began trading on the exchange under the tic…
- Virtuoso Surgical nabs FDA authorization for robotic bladder lesions systemThe FDA has granted De Novo authorization for Virtuoso Surgical’s Virtuoso Endoscopy System.Fierce Biotech · 5h ago↗ source